Transdermal Scopolamine for Prevention of Motion Sickness: Clinical Pharmacokinetics and Therapeutic Applications

Author： Nachum Zohar   Shupak Avi   Gordon Carlos R.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.45, Iss.6, 2006-01, pp. : 543-566

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention and Treatment of Motion Sickness in Children

By Gordon C.R.  

CNS Drugs, Vol. 12, Iss. 5, 1999-11 ,pp. : 369-381

Adis International

Access to resources Recommend Favorite

Scopolamine Sublingual Spray: An Alternative Route of Delivery for the Treatment of Motion Sickness

By Al-Ghananeem Abeer M.   Malkawi Ahmad H.   Crooks Peter A.  

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 5, 2007-05 ,pp. : 577-582

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Transdermal Opioids: Focus on Transdermal Fentanyl

By Grond S.   Radbruch L.   Lehmann K.A.  

Clinical Pharmacokinetics, Vol. 38, Iss. 1, 2000-01 ,pp. : 59-89

Adis International

Access to resources Recommend Favorite

Oral Mucosal Drug Delivery: Clinical Pharmacokinetics and Therapeutic Applications

By Zhang H.  

Clinical Pharmacokinetics, Vol. 41, Iss. 9, 2002-01 ,pp. : 661-680

Adis International

Access to resources Recommend Favorite

Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo

By Klocker N.   Hanschke W.   Toussaint S.   Verse T.  

European Journal of Pharmaceutical Sciences, Vol. 13, Iss. 2, 2001-05 ,pp. : 227-232

Elsevier

Access to resources Recommend Favorite